US 11,958,882 B2
Methods directed to crystalline biomolecules
Rizwan Sharnez, Mead, CO (US); William Trieu, Agoura Hills, CA (US); Marc A. Caporini, Cambridge, MA (US); Ron C. Kelly, Thousand Oaks, CA (US); Neill Burt, Denver, CO (US); Laura Nicholson, Boulder, CO (US); and Twinkle R. Christian, Thousand Oaks, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Appl. No. 16/494,165
Filed by AMGEN INC., Thousand Oaks, CA (US)
PCT Filed Mar. 14, 2018, PCT No. PCT/US2018/022387
§ 371(c)(1), (2) Date Sep. 13, 2019,
PCT Pub. No. WO2018/170098, PCT Pub. Date Sep. 20, 2018.
Claims priority of provisional application 62/476,359, filed on Mar. 24, 2017.
Claims priority of provisional application 62/471,358, filed on Mar. 14, 2017.
Prior Publication US 2020/0157141 A1, May 21, 2020
Int. Cl. C30B 7/10 (2006.01); A61K 39/395 (2006.01); B01J 8/20 (2006.01); B01J 8/38 (2006.01); C07K 1/30 (2006.01); C30B 7/00 (2006.01); C30B 30/04 (2006.01); G01N 24/08 (2006.01); C30B 30/00 (2006.01); C30B 30/02 (2006.01); G01N 24/00 (2006.01); G01R 33/20 (2006.01); G01R 33/46 (2006.01)
CPC C07K 1/306 (2013.01) [A61K 39/39591 (2013.01); B01J 8/20 (2013.01); B01J 8/38 (2013.01); C30B 7/00 (2013.01); C30B 7/10 (2013.01); C30B 30/04 (2013.01); G01N 24/087 (2013.01); C30B 30/00 (2013.01); C30B 30/02 (2013.01); G01N 24/00 (2013.01); G01N 24/008 (2013.01); G01R 33/20 (2013.01); G01R 33/46 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method of preparing a composition comprising crystalline biomolecules, comprising:
a) forming a fluidized bed of crystalline biomolecules in a rotating chamber comprising an inlet and an outlet, wherein the fluidized bed is created by rotating the chamber about a substantially horizontal axis to create a centrifugal force (Fcentrifugal) in said chamber, flowing a first stream of a first solution through the inlet in a direction opposite to the direction of the Fcentrifugal and at a first flow rate (FR1) having a force (FFR1) which counter balances Fcentrifugal, and collecting the first solution from the chamber while substantially maintaining the formation of the fluidized bed of crystallized biomolecules;
b) performing step (i), (ii), or (iii):
i. flowing a second stream of a second solution to replace the first stream of the first solution while substantially maintaining the formation of the fluidized bed of crystallized biomolecules;
ii. concentrating the crystallized biomolecules within a region of the chamber by changing FR1 to a second flow rate (FR2) having a force (FFR2) which is less than Fcentrifugal or by increasing the speed of rotation of the chamber to increase Fcentrifugal to a level which is greater than FFR1;
iii. a combination of step (i) and step (ii); and
c) flowing a second stream into the chamber through the outlet in a direction which is parallel to the direction of the Fcentrifugal to crystalline remove the crystalline biomolecules from the chamber.